(Q34083121)

English

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

0 references

0 references

author name string

E A Mittendorf

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

G T Clifton

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J P Holmes

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

E Schneble

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

D van Echo

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Ponniah

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

G E Peoples

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1735-1742

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

From vaccines to memory and back

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

The E75 HER2/neu peptide vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

The future of interleukin-2: enhancing therapeutic anticancer vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

Cytotoxic T-cell memory without antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

5 July 2018

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143091

28 October 2018

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24907636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/24907636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24907636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDU211

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34083121&oldid=1752708145"